3rd June, 2020

The COVID-19 pandemic and NOVELTY

The COVID-19 pandemic is a key transformative event in the lifetime of the NOVELTY study. The NOVELTY study provides a unique opportunity to better understand the risk and outcomes of COVID-19 infection in patients with asthma and/or COPD.
Read More

18th March, 2020

An update on NOVELTY governance: the NOVELTY Scientific Community

The NOVELTY Scientific Community was established at the annual face-to-face meeting on 22 January 2020. This new structure represents an evolution in the NOVELTY scientific strategy, setting and delivery, bringing together the separate bodies of the Scientific Committee, the National Principal Investigators and the AstraZeneca science and evidence leads.
Read More

10th December, 2019

Severe obstructive lung disease review article published

We are pleased to announce that a review article entitled ‘Defining severe obstructive lung disease in the biologic era: an endotype-based approach’ has been published in the European Respiratory Journal.
Read More

7th April, 2016

A message from the NOVELTY Scientific Committee

We are very pleased to announce the launch of the NOVELTY study, and are enthusiastic to be working with physicians and study centres around the world to increase our knowledge of obstructive lung disease on a global, local and individual patient level.
Read More